Cynosure Group LLC Grows Holdings in Humana Inc. (NYSE:HUM)

Cynosure Group LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 11.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,324 shares of the insurance provider’s stock after purchasing an additional 133 shares during the quarter. Cynosure Group LLC’s holdings in Humana were worth $419,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HUM. Mendota Financial Group LLC lifted its stake in shares of Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares in the last quarter. Capital Advisors Ltd. LLC lifted its position in shares of Humana by 17.0% in the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after acquiring an additional 31 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its stake in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the period. Moors & Cabot Inc. grew its position in shares of Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares in the last quarter. Finally, Harbour Investments Inc. raised its stake in Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after purchasing an additional 41 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Humana stock opened at $296.83 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $35.74 billion, a P/E ratio of 26.29, a price-to-earnings-growth ratio of 2.40 and a beta of 0.52. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $526.47. The company’s 50-day moving average is $275.91 and its 200 day moving average is $330.00.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Research analysts forecast that Humana Inc. will post 15.86 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is currently 31.36%.

Analyst Ratings Changes

Several research firms have weighed in on HUM. Royal Bank of Canada dropped their price target on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Stephens reissued an “equal weight” rating and issued a $250.00 target price on shares of Humana in a report on Wednesday, October 9th. Wells Fargo & Company cut their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Truist Financial decreased their price target on shares of Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research note on Friday, October 11th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.